Defibrotide - Jazz Pharmaceuticals

Drug Profile

Defibrotide - Jazz Pharmaceuticals

Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; Prociclide

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gentium
  • Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Swedish Orphan Biovitrum
  • Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Veno-occlusive disorders; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Veno-occlusive disorders
  • Phase II Graft-versus-host disease
  • Market Withdrawal Deep vein thrombosis; Thrombosis
  • No development reported Diabetic nephropathies; Multiple myeloma

Most Recent Events

  • 17 Oct 2018 Preregistration for Veno-occlusive disorders in Japan (IV)
  • 19 Sep 2018 Defibrotide - Jazz Pharmaceuticals receives Orphan Drug status for Veno-occlusive disorders in Japan
  • 19 Sep 2018 Nippon Shinyaku announces intention to submit regulatory filing to the Ministry of Health, Labour and Welfare for Veno-occlusive disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top